Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Amgen Inc.NASDAQ: AMGN

Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026

Change in working capital turns positive

Q2 FY2026 change in working capital was $408M, compared with -$759M a year earlier. Trailing-twelve-month change in working capital was -$516M. Over 3 fiscal years it compounded at +39.2% a year.

Context

  • Change in working capital amounted to 5.4% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near $408M or moves back toward the trailing-twelve-month quarterly average of -$129M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$408M+156.6% QoQ
Last fiscal yearDec 2025
-$1.98B-183.6% YoY
LTMJun 2026
-$516M-144.5% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+153.8%——
1 year-183.6%——
3-year CAGR+39.2%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(1.98B) USD
Year-over-year change
-183.6%

Change in Working Capital vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -144.5% is the 7th highest of 10, against a peer median of -38.9%.
  • Change in working capital amounts to 1.4% of revenue for AMGN, versus a peer median of 4.5%.
AMGN Competitors
Change in Working Capital for AMGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$11.68B USD-1563.0%+46.9%11.8%
LLYEli Lilly and CompanyLTM Jun 2026$4.8B USD-38.9%+2062.8%6.0%
ABBVAbbVie Inc.LTM Jun 2026$3.86B USD+38.5%+109.2%6.0%
AZNAstraZeneca PLCLTM Sep 2026$2.95B USD+931.3%—4.7%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$2.23B USD-297.4%-41.1%4.5%
NVSNovartis AGLTM Jun 2026$2.03B USD+308.2%+56.9%3.6%
PFEPfizer Inc.LTM Jun 2026$1.99B USD-35.7%+6.3%3.1%
MRKMerck & Co., Inc.LTM Jun 2026$1.25B USD-76.1%+35.9%1.9%
GSKGSK plcLTM Jun 2026£777.4M GBP-164.8%-28.6%2.3%
AMGNAmgen Inc.LTM Jun 2026$516M USD-144.5%+39.2%1.4%
Peer median (excluding AMGN) —-38.9%+41.4%4.5%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.89B6.55B6.72B4.09B7.71B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
Deferred Income Tax(453M)(1.2B)(1.27B)(1.23B)(721M)
Stock-Based Compensation341M401M431M530M494M
Change in Working Capital(1.19B)(733M)(484M)2.37B(1.98B)
Accounts Receivables(429M)(746M)(1.02B)441M(2.68B)
Inventory(165M)(742M)491M2.53B886M
Accounts Payables(69M)154M(402M)312M428M
Other Working Capital(531M)601M442M(920M)(616M)
Other Non-Cash Items1.28B1.28B(991M)141M(715M)
Operating Cash Flow9.26B9.72B8.47B11.49B9.96B
Capital Expenditures(880M)(936M)(1.11B)(1.1B)(1.86B)
Acquisitions (Net)(2.69B)(3.73B)(26.99B)0(53M)
Purchases of Investments(8.9B)(2.59B)(1M)00
Sales of Investments13.23B1.22B1.67B00
Other Investing Activities(35M)(12M)225M50M(32M)
Investing Cash Flow733M(6.04B)(26.2B)(1.05B)(1.94B)
Debt Repayment795M6.62B25.68B(4.26B)(5.68B)
Common Stock Issued00000
Common Stock Repurchased(4.98B)(6.36B)0(200M)0
Dividends Paid(4.01B)(4.2B)(4.56B)(4.83B)(5.12B)
Other Financing Activities(78M)(103M)(72M)(124M)(52M)
Financing Cash Flow(8.27B)(4.04B)21.05B(9.42B)(10.86B)
Effect of Forex Changes00000
Net Change in Cash1.72B(360M)3.32B1.03B(2.84B)
Free Cash Flow8.38B8.79B7.36B10.39B8.1B

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.